The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > REGULATORY
REGULATORY
- 17 Anaphylaxis Cases Now Reported in Japan’s COVID-19 Vaccine Program
March 10, 2021
- Govt Won’t Widely Recommend Use of 7-Dose Syringes for Pfizer Vaccine: Top Spokesman
March 10, 2021
- Medical Institutions Would Be Allowed to Provide 7 Doses per Vial of Pfizer’s COVID-19 Vaccine: Health Minister
March 10, 2021
- PMDA to Launch Working Group in April to Step Up Use of RWD
March 10, 2021
- Japan to Consider Ways to Speed Up Ivermectin Research for COVID-19
March 9, 2021
- Imfinzi, 2 Other Drugs under PMDA Safety Review
March 8, 2021
- Japan Speeds Up Vaccine Delivery for HCPs, Kono Says All 2nd Doses to Reach Municipalities in 1st Half of May
March 8, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Vaccine Minister Says Govt to Stick to 3 Week Interval for Now
March 4, 2021
- MHLW Weighs 6-Week Dosing Interval for Pfizer Vaccine
March 4, 2021
- Vaccine Freezer Breakdown Due to Power Shortage: MHLW
March 4, 2021
- Nichi-Iko Ordered to Suspend Biz over Sloppy Manufacturing
March 3, 2021
- All Municipalities to Get 1 Carton of COVID-19 Vaccines for Elderly in Final Week of April: MHLW
March 3, 2021
- Freezers for Moderna Vaccine Could Be Used for Comirnaty Too: Campaign Minister
March 3, 2021
- Woman Dies 3 Days after COVID-19 Vaccine Shot, but Link Indeterminable
March 3, 2021
- MHLW Unveils List of “Stable Supply Medicines”
March 2, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…